Advertisement

Search Results

Advertisement



Your search for ASCO Post matches 17606 pages

Showing 1 - 50


breast cancer
genomics/genetics

How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival

A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....

issues in oncology

Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer

Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...

lymphoma

FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma

On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...

lymphoma
immunotherapy

Study Identifies Key LBCL Traits Tied to Greatest Benefit From CD19 CAR T-Cell Therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center have identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19-targeted chimeric antigen receptor (CAR) T cell therapy. In the study,...

cardio-oncology

Elevated Cardiac Biomarkers Associated With Increased Cancer Risk

Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...

solid tumors
supportive care
symptom management

Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder

A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...

solid tumors
colorectal cancer

Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies

The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...

breast cancer
lymphoma
issues in oncology
genomics/genetics

BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment

The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...

head and neck cancer

Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers

Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...

leukemia

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations

A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...

hematologic malignancies

Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis

Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial. This was the first U.S. trial of CAR T-cell therapy for patients with AL amyloidosis, demonstrating...

breast cancer

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...

prostate cancer

Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations

Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...

colorectal cancer

Colorectal Cancer Screening: CT Colonography vs Stool Testing

Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology.   "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...

head and neck cancer
immunotherapy

FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer

Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...

geriatric oncology
supportive care
global cancer care

Could A Telehealth Program Enhance Geriatric Cancer Care?

A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...

bladder cancer

FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. Mitomycin intravesical solution is a reverse thermal hydrogel formulation of mitomycin...

issues in oncology

CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays

Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...

supportive care
gynecologic cancers

Nomogram Model May Predict DVT Risk in Patients With Ovarian Cancer

Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society.   A number of significant independent risk factors for DVT...

lung cancer

FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) talectrectinib (Ibtrozi) for the treatment of adults with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC). Investigators reported that the agent has ...

gastrointestinal cancer

Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945

A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...

skin cancer

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma

In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...

gynecologic cancers

Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings

Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...

solid tumors
gynecologic cancers
thyroid cancer
pancreatic cancer
prostate cancer
issues in oncology

Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests

Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...

prostate cancer

AACR Statement on Former President Joseph Biden’s Cancer Diagnosis

The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...

gynecologic cancers

I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer

More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...

MD Anderson Names Jeffrey E. Lee, MD, Chief Medical Executive

The University of Texas MD Anderson Cancer Center announced that Jeffrey E. Lee, MD, an internationally regarded leader in the field of oncology, has been appointed Chief Medical Executive (CME). Prior to his appointment, Dr. Lee served as CME ad interim. Assuming the role of CME is the...

hematologic malignancies

Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma

Although treatment with the bispecific antibody teclistamab was approved for patients with relapsed or refractory multiple myeloma, based on the MajesTEC-1 study results, only 15% of patients in the phase I/II trial were aged 75 or older. To learn more about the safety and efficacy of this agent in ...

colorectal cancer

ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers

In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...

issues in oncology
breast cancer

Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women

The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...

cost of care
issues in oncology

ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care

Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...

colorectal cancer

Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent

The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The FDA also...

issues in oncology

How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research

Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...

lung cancer

Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...

breast cancer

Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer

“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...

skin cancer
genomics/genetics
immunotherapy

Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma

Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...

solid tumors
issues in oncology

Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis

Genetic material shed by tumors may be detected in the bloodstream 3 years prior to cancer diagnosis, according to a recent study published by Wang et al in Cancer Discovery. Study Methods and Results Researchers used highly accurate and sensitive sequencing techniques to analyze the plasma samples ...

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). ...

immunotherapy
genomics/genetics

Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504). 

ACS CAN Statement on Federal Cuts to Cancer Research

On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year.   The following is a statement from...

breast cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...

breast cancer
issues in oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do...

prostate cancer

Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade

Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract...

prostate cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

supportive care
pain management

Treatment for Intractable Cancer Pain Pioneered

A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...

issues in oncology

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well...

issues in oncology

Are Most Americans Aware of the Link Between Alcohol and Cancer Risk?

Although alcohol consumption is a known leading preventable cause of cancer, public awareness of the connection may remain concerningly low in the United States, according to a recent study published by Domgue et al in JAMA Oncology. Background Consuming alcohol has been linked to at least seven...

lung cancer

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose...

lung cancer

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with...

leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual ...

Advertisement

Advertisement




Advertisement